These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25092538)

  • 21. Expression and predictive value of lymph-specific markers in urothelial carcinoma of the bladder.
    von Hardenberg J; Martini T; Knauer A; Ströbel P; Becker A; Herrmann E; Schubert C; Steidler A; Bolenz C
    Urol Oncol; 2014 Jan; 32(1):54.e9-17. PubMed ID: 24360666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic implications of extracapsular extension of pelvic lymph node metastases in urothelial carcinoma of the bladder.
    Fleischmann A; Thalmann GN; Markwalder R; Studer UE
    Am J Surg Pathol; 2005 Jan; 29(1):89-95. PubMed ID: 15613859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder.
    May M; Bastian PJ; Brookman-May S; Burger M; Bolenz C; Trojan L; Michel MS; Herrmann E; Wülfing C; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Wieland WF; Gilfrich C; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Gunia S; Fritsche HM
    Scand J Urol Nephrol; 2011 Sep; 45(4):251-7. PubMed ID: 21388337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 expression in patients with advanced urothelial cancer of the urinary bladder.
    Shariat SF; Bolenz C; Karakiewicz PI; Fradet Y; Ashfaq R; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Rigaud J; Müller SC; Lerner SP; Montorsi F; Sagalowsky AI; Cote RJ; Lotan Y
    BJU Int; 2010 Feb; 105(4):489-95. PubMed ID: 19659466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer.
    Schuettfort VM; Pradere B; Trinh QD; D'Andrea D; Quhal F; Mostafaei H; Laukhtina E; Mori K; Sari Motlagh R; Rink M; Karakiewicz PI; Chlosta P; Yuen-Chun Teoh J; Lotan Y; Scherr D; Abufaraj M; Moschini M; Shariat SF
    Cancer Immunol Immunother; 2022 Jan; 71(1):85-95. PubMed ID: 34023914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.
    Rink M; Hansen J; Cha EK; Green DA; Babjuk M; Svatek RS; Xylinas E; Tagawa ST; Faison T; Novara G; Karakiewicz PI; Daneshmand S; Lotan Y; Kassouf W; Fritsche HM; Pycha A; Comploj E; Tilki D; Bastian PJ; Chun FK; Dahlem R; Scherr DS; Shariat SF
    BJU Int; 2013 Jan; 111(1):74-84. PubMed ID: 22809039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.
    Rink M; Park K; Volkmer BG; Xylinas E; Hansen J; Cha EK; Robinson BD; Hautmann R; Küfer R; Engel O; Chun FK; Dahlem R; Rubin MA; Shariat SF; Mosquera JM
    Urol Oncol; 2013 Nov; 31(8):1716-24. PubMed ID: 22944196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder.
    Mayr R; May M; Burger M; Martini T; Pycha A; Dechet C; Lodde M; Comploj E; Wieland WF; Denzinger S; Otto W; Aziz A; Fritsche HM; Gierth M
    Urol Int; 2014; 93(3):303-10. PubMed ID: 25139069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy.
    da Silva RD; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Chade D; Guglielmetti GB; Pycha A; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Zerbib M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):487-92. PubMed ID: 23395802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
    Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
    Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
    Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
    Rink M; Chun FK; Dahlem R; Soave A; Minner S; Hansen J; Stoupiec M; Coith C; Kluth LA; Ahyai SA; Friedrich MG; Shariat SF; Fisch M; Pantel K; Riethdorf S
    Eur Urol; 2012 Apr; 61(4):810-7. PubMed ID: 22277196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
    Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder.
    Wang LC; Xylinas E; Kent MT; Kluth LA; Rink M; Jamzadeh A; Rieken M; Al Hussein Al Awamlh B; Trinh QD; Sun M; Karakiewicz PI; Novara G; Chrystal J; Zerbib M; Scherr DS; Lotan Y; Vickers A; Shariat SF
    Urol Oncol; 2014 May; 32(4):433-40. PubMed ID: 24433754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Cancer of the Bladder Risk Assessment (COBRA) score for predicting cancer-specific survival after radical cystectomy for urothelial carcinoma of the bladder: External validation in a cohort of Korean patients.
    Kim HS; Kwak C; Kim HH; Ku JH
    Urol Oncol; 2019 Jul; 37(7):470-477. PubMed ID: 30935845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.